First-Line Therapy for Human Cutaneous Leishmaniasis in Peru Using the TLR7 Agonist Imiquimod in Combination with Pentavalent Antimony

BACKGROUND: Current therapies for cutaneous leishmaniasis are limited by poor efficacy, long-term course of treatment, and the development of resistance. We evaluated if pentavalent antimony (an anti-parasitic drug) combined with imiquimod (an immunomodulator) was more effective than pentavalent ant...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Principais autores: Miranda-Verastegui, Cesar, Tulliano, GianFranco, Gyorkos, Theresa W., Calderon, Wessmark, Rahme, Elham, Ward, Brian, Cruz, Maria, Llanos-Cuentas, Alejandro, Matlashewski, Greg
Formato: Artigo
Idioma:Inglês
Publicado em: Public Library of Science 2009
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2710502/
https://ncbi.nlm.nih.gov/pubmed/19636365
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pntd.0000491
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados